Nature Technology Corporation is a discovery-based bioengineering technology company, providing industry solutions for biopharmaceutical development: vectors; strains; processes; and products; including manufacturing and technology transfer. NTC specializes in services and products for manufacturing recombinant plasmids (gene therapeutics and DNA vaccines) and proteins. NTC's platform technologies are available to industry partners with promising new age gene drugs.
Nature Technology Corporation (NTC) does not currently have an SEC registered investment opportunity. The company is interested in acquiring and/or consolidating with complimentary front-runners in the fields of gene based medicines (gene therapy and DNA vaccines). As such, corporate and private equity partnering/financing inquiries are invited.
Dr. Clague Hodgson, CEO:
hodgson@natx.com